Persistent, NVIDIA Team Up on AI Molecule Generation and Virtual Drug Screening

An update from Persistent Systems Limited ( (IN:PERSISTENT) ) is now available.

Persistent Systems has launched an AI-powered Generative Molecules and Virtual Screening solution, developed in collaboration with NVIDIA, to target early-stage drug discovery for healthcare and life sciences organizations. By using NVIDIA’s full-stack AI platform, including NVIDIA AI Enterprise and the BioNeMo framework, the company aims to enable high-fidelity molecular simulation and large-scale virtual screening, helping life sciences enterprises shift from AI pilots to mission-critical production use in preclinical research and computational drug discovery.

The new GenMoIVS solution, built with NVIDIA NeMo, is designed to model real-world biological and chemical behavior in silico before experiments move into wet lab environments. This initiative positions Persistent as a deeper technology partner to pharmaceutical and biotech firms seeking to accelerate R&D, potentially shortening discovery timelines and improving research outcomes in a highly regulated and data-intensive industry.

More about Persistent Systems Limited

Persistent Systems is a global digital engineering and enterprise modernization company that develops software and AI-driven solutions for clients across sectors, with a growing focus on healthcare and life sciences. The company leverages partnerships with major technology providers and full-stack AI platforms to deliver production-grade applications that help enterprises scale from experimentation to real-world deployments.

Average Trading Volume: 46,009

Technical Sentiment Signal: Hold

Current Market Cap: 732.6B INR

See more insights into PERSISTENT stock on TipRanks’ Stock Analysis page.